Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Zohar

Showing results (1-10 of 89) with videos related to

Pageof 9
Sort By:
Journal of Biopharmaceutical Statistics|August 20, 2010
Retrospective robustness of the continual reassessment methodJohn O'Quigley, Sarah Zohar
Statistics in Medicine|September 14, 2006
Optimal designs for estimating the most successful doseSarah Zohar, John O'Quigley
Journal of the National Cancer Institute|November 7, 2009
Re: Dose escalation methods in phase I cancer clinical trialsSarah Zohar, John O'Quigley
Contemporary Clinical Trials|July 8, 2009
Sensitivity of dose-finding studies to observation errorsSarah Zohar, John O'Quigley
Pharmaceutical Statistics|November 4, 2006
Identifying the most successful dose (MSD) in dose-finding studies in cancerSarah Zohar, John O'Quigley
Journal of Biopharmaceutical Statistics|November 21, 2007
Recent developments in adaptive designs for Phase I/II dose-finding studiesSarah Zohar, Sylvie Chevret
Journal of Biopharmaceutical Statistics|March 15, 2003
Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian designSarah Zohar, Sylvie Chevret
Clinical Pharmacokinetics|August 5, 2009
A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncologyEmmanuelle Comets, Sarah Zohar
Pharmaceutical Statistics|June 27, 2013
An adaptive model switching approach for phase I dose-finding trialsTakashi Daimon, Sarah Zohar
Biometrics|May 31, 2024
Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati BiswasMoreno Ursino, Sarah Zohar
Pageof 9

Showing results (1-10 of 89) with videos related to

Sort By:
Pageof 9
Journal of Biopharmaceutical Statistics|August 20, 2010
Retrospective robustness of the continual reassessment methodJohn O'Quigley, Sarah Zohar
Statistics in Medicine|September 14, 2006
Optimal designs for estimating the most successful doseSarah Zohar, John O'Quigley
Journal of the National Cancer Institute|November 7, 2009
Re: Dose escalation methods in phase I cancer clinical trialsSarah Zohar, John O'Quigley
Contemporary Clinical Trials|July 8, 2009
Sensitivity of dose-finding studies to observation errorsSarah Zohar, John O'Quigley
Pharmaceutical Statistics|November 4, 2006
Identifying the most successful dose (MSD) in dose-finding studies in cancerSarah Zohar, John O'Quigley
Journal of Biopharmaceutical Statistics|November 21, 2007
Recent developments in adaptive designs for Phase I/II dose-finding studiesSarah Zohar, Sylvie Chevret
Journal of Biopharmaceutical Statistics|March 15, 2003
Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian designSarah Zohar, Sylvie Chevret
Clinical Pharmacokinetics|August 5, 2009
A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncologyEmmanuelle Comets, Sarah Zohar
Pharmaceutical Statistics|June 27, 2013
An adaptive model switching approach for phase I dose-finding trialsTakashi Daimon, Sarah Zohar
Biometrics|May 31, 2024
Discussion on "Bayesian meta-analysis of penetrance for cancer risk" by Thanthirige Lakshika M. Ruberu, Danielle Braun, Giovanni Parmigiani, and Swati BiswasMoreno Ursino, Sarah Zohar
Pageof 9